Akoya Biosciences Net Tangible Assets Over Time
| AKYA Stock | USD 2.20 0.06 2.80% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Akoya Biosciences Performance and Akoya Biosciences Correlation. Akoya |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akoya Biosciences. If investors know Akoya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akoya Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.16) | Revenue Per Share 1.889 | Quarterly Revenue Growth (0.01) | Return On Assets (0.18) | Return On Equity (1.28) |
The market value of Akoya Biosciences is measured differently than its book value, which is the value of Akoya that is recorded on the company's balance sheet. Investors also form their own opinion of Akoya Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Akoya Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akoya Biosciences' market value can be influenced by many factors that don't directly affect Akoya Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akoya Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Akoya Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akoya Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Tangible Assets Analysis
Compare Akoya Biosciences and related stocks such as AtriCure, ATRION, and ICU Medical Net Tangible Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATRC | 15.6 M | 15.6 M | 12.5 M | 26.9 M | 88.3 M | 27.7 M | 11.1 M | 5.1 M | 94.9 M | (117.3 M) | 49.4 M | 206 M | 182.6 M | 210 M | 220.5 M |
| ICUI | 246.7 M | 307.7 M | 379.4 M | 454.8 M | 499.7 M | 549.5 M | 632.2 M | 1 B | 1.1 B | 1.2 B | 1.3 B | 1.6 B | (342.1 M) | (393.4 M) | (373.7 M) |
| HAE | 469 M | 521 M | 174.3 M | 230 M | 247.2 M | 249.3 M | 351.2 M | 384.4 M | 329.4 M | 243.4 M | (100.3 M) | (28.1 M) | 76 M | 68.4 M | 65 M |
| ANGO | 67.3 M | 67.3 M | (28.9 M) | (28.9 M) | 2.2 M | (20.6 M) | 8.1 M | 51 M | 121.8 M | 57.2 M | 69.2 M | 71.1 M | 378.3 M | 435 M | 456.8 M |
| ATR | 1 B | 1.1 B | 976.4 M | 733.6 M | 733.6 M | 807.6 M | 671.9 M | 772.4 M | 455.6 M | 1.6 B | 607.6 M | 995.2 M | 792.6 M | 713.3 M | 702.6 M |
| COO | 290.6 M | 607.7 M | (104.6 M) | (104.6 M) | 59.3 M | 94 M | 316.2 M | (605.8 M) | (205.8 M) | 88.3 M | 3.1 B | 1.7 B | 2.2 B | 2.5 B | 2.7 B |
| INFU | 11.9 M | 11.9 M | 18.5 M | 18.5 M | 21.4 M | 18.8 M | 19.4 M | 31 M | 576 K | 22.3 M | 29.6 M | 33.6 M | 44.3 M | 50.9 M | 53.5 M |
| PDEX | 9.6 M | 9.6 M | 7.9 M | 9.1 M | 7.6 M | 8.3 M | 13.3 M | 17.1 M | 16.9 M | 18.9 M | 19.9 M | 23.6 M | 31.5 M | 36.2 M | 38 M |
| LMAT | 37.2 M | 37.2 M | 33.9 M | 35.4 M | 43.8 M | 53.8 M | 54.2 M | 77.7 M | 86.7 M | 108.2 M | 113.7 M | 135.5 M | 155.7 M | 179.1 M | 188 M |
| UTMD | (13.8 M) | (13.8 M) | (5.8 M) | 70.1 M | 64.6 M | 69.6 M | 69.2 M | 78.1 M | 60.5 M | 56.9 M | 64.7 M | 75.7 M | 90.5 M | 104.1 M | 62.4 M |
| MLSS | 1.2 M | 1.2 M | 1.3 M | 4.9 M | 14.1 M | 9.6 M | 7.8 M | 7.2 M | 1.1 M | 1.3 M | 15.9 M | 16.1 M | 16.1 M | 18.5 M | 19.4 M |
Akoya Biosciences and related stocks such as AtriCure, ATRION, and ICU Medical Net Tangible Assets description
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.My Equities
My Current Equities and Potential Positions
| Akoya Biosciences | AKYA |
Specialization | Health Care, Health Care Equipment & Services |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.2
Check out Akoya Biosciences Performance and Akoya Biosciences Correlation. For information on how to trade Akoya Stock refer to our How to Trade Akoya Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Akoya Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.